Table 5 Comparison of medication prescription at admission and discharge in MINOCA, MIOCA and Control
Variable | Studies (n) | Pooled Prevalence of each Variable in Study Groups | Â | MIOCA Vs MINOCA (OR (95% CI)) | P-value for OR=1 | Cochrane Q | I2 (%) | P-value for Egger Test | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | Â | Â | Â | Sample Size/ Total MIOCA | Pooled Prevalenc in MIOCA (%) | Sample Size/ Total MINOCA | Pooled Prevalenc in MINOCA (%) | Â | Â | Â | Â | Â |
Treatment at Admissiona | Routine Drugs | Statin | 16 | 737681/ 1379552 | 53.33 (53.25, 53.42) | 121714/ 258800 | 23.94 (23.08, 24.8) | 1.38 (1.17, 1.62) | 0.001> | 429.79 | 96.5 | 0.516 |
β-blockers | 18 | 883140/ 1389729 | 63.62 (63.54, 63.7) | 137153/ 260314 | 52.65 (52.46, 52.84) | 1.51 (1.22, 1.85) | 0.001> | 1165.45 | 98.5 | 0.786 | ||
CCB | 8 | 7003/ 33945 | 19.44 (19.02, 19.87) | 1916/ 9967 | 18.53 (17.76, 19.31) | 1.06 (0.84, 1.35) | 0.614 | 43.22 | 83.8 | 0.812 | ||
Anti-Platelet | Aspirin | 16 | 1131826/ 1432719 | 80.12 (80.05, 80.18) | 187387/ 261664 | 71.91 (71.73, 72.08) | 1.28 (0.85, 1.94) | 0.242 | 3505.2 | 99.6 | 0.09 | |
Clopidogrel | 9 | 742540/ 1317415 | 55.68 (55.59, 55.76) | 59932/ 242490 | 24.43 (24.26, 24.61) | 1.67 (0.4, 6.88) | 0.478 | 2920.43 | 99.7 | 0.249 | ||
P2Y12-Inhibitor | 5 | 3995/ 100355 | 3.49 (3.38, 3.61) | 773/ 16671 | 4.16 (3.85, 4.47) | 1.53 (1.02, 2.31) | 0.041 | 58.66 | 93.2 | 0.503 | ||
Any Anti-Platelet | 2 | 6348/ 7878 | 81.05 (80.17, 81.91) | 637/ 1018 | 62.68 (59.67, 65.64) | 2.32 (2.01, 2.68) | 0.001> | 0.05 | 0 | 0.001> | ||
Anti-Coagulant | Warfarin | 1 | 118/ 3630 | 3.25 (2.7, 3.88) | 15/ 200 | 7.5 (4.26, 12.07) | 0.41 (0.24, 0.72) | 0.002 | NA | NA | NA | |
Heparin | 1 | 1556/ 2761 | 56.36 (54.48, 58.22) | 54/ 142 | 38.03 (30.02, 46.55) | 2.1 (1.49, 2,98) | 0.001> | NA | NA | NA | ||
LMWH | 1 | 1626/ 2761 | 58.89 (57.03, 60.73) | 94/ 142 | 66.2 (57.79, 73.91) | 0.73 (0.51, 1.04) | 0.085 | NA | NA | NA | ||
Any-Anti-Coagulant | 3 | 2899/ 95812 | 3.02 (2.91, 3.12) | 498/ 9527 | 5.2 (4.76, 5.66) | 0.56 (0.51, 0.62) | 0.001> | 1.07 | 0 | 0.23 | ||
ACE-I and/or ARB | RAAS-I (ACE-I + ARB) | 3 | 7781/ 22509 | 34.24 (33.62, 34.86) | 683/ 1985 | 34.28 (32.3, 36.4) | 1.17 (0.7, 1.95) | 0.546 | 25.37 | 92.1 | 0.296 | |
ACE-I | 6 | 8150/ 23744 | 34.01 (33.41, 34.62) | 2502/ 9507 | 25.96 (25.07, 26.85) | 1.33 (1.09, 1.63) | 0.005 | 26.83 | 81.4 | 0.142 | ||
ARB | 2 | 1952/ 7952 | 24.43 (23.49, 25.39) | 265/ 1319 | 19.36 (17.22, 21.6) | 5.82 (0.16, 214.74) | 0.339 | 6.71 | 85.1 | 0.001> | ||
ACE-I and/or ARB | 10 | 13549/ 28660 | 46.89 (46.31, 47.47) | 2098/ 4757 | 43.43 (42.02, 44.86) | 1.49 (1.16, 1.92) | 0.002 | 63.57 | 85.8 | 0.188 | ||
CombinationTherapy (e.g., Aspirin + Clopidogrel) | 2 | 104/ 595 | 17.19 (14.25, 20.35) | 379/ 2161 | 16.98 (15.38, 18.64) | 0.58 (0.12, 2.72) | 0.489 | 9.94 | 89.9 | 0.001> | ||
Diuretics | 3 | 1228/ 5613 | 21.78 (20.7, 22.87) | 47/ 346 | 13.5 (10.05, 17.36) | 1.67 (1.2, 2.31) | 0.002 | 0.8 | 0 | 0.76 | ||
Insulin | 2 | 298/ 2858 | 10.24 (9.14, 11.4) | 12/ 239 | 4.39 (2.05, 7.47) | 2.62 (0.47, 14.51) | 0.27 | 2.7 | 63 | 0.001> | ||
Treatment at Dischargea | Routine Drugs | Statin | 26 | 320427/ 385450 | 85.09 (84,98, 85.2) | 26264/ 35197 | 76.07 (75.62, 76.52) | 2.15 (1.23, 3.77) | 0.007 | 7148.22 | 99.7 | 0.047 |
β-blockers | 26 | 168956/ 223566 | 77.36 (77.19, 77.54) | 18672/ 28730 | 66.15 (65.6, 66.7) | 2.16 (1.15, 4.07) | 0.017 | 8143.30 | 99.7 | 0.282 | ||
CCB | 9 | 1228/ 16921 | 6.22 (5.84, 6.6) | 394/ 1220 | 30.76 (28.17, 33.41) | 0.37 (0.14, 1.07) | 0.051 | 238.75 | 96.8 | 0.145 | ||
Anti-Platelet | Aspirin | 24 | 402008/ 487533 | 85.08 (84.98, 85.18) | 23966/ 29355 | 83.2 (82.77, 83.63) | 2.92 (1.54, 5.52) | 0.001 | 6612.40 | 99.7 | 0.003 | |
Clopidogrel | 9 | 75207/ 146941 | 51.49 (51.24, 51.75) | 3204/ 8107 | 39.41 (38.34, 40.48) | 5.2 (2.67, 10.15) | 0.001> | 733.08 | 98.9 | 0.06 | ||
P2Y12-Inhibitor | 9 | 230912/ 298482 | 78.39 (78.24, 78.53) | 12901/ 18902 | 68.55 (67.88, 69.22) | 3.53 (0.9, 13.91) | 0.071 | 10092.57 | 99.9 | 0.22 | ||
Any-Anti-Platelet | 3 | 5404/ 7413 | NA | 176/ 524 | 32.61 (28.59, 36.75) | 6.88 (3.84, 12.31) | 0.001> | 3.73 | 46.4 | 0.424 | ||
Anti-Coagulant | Anti-Coagulant | 2 | 50/ 567 | 8.71 (6.49, 11.21) | 20/ 218 | 8.35 (4.96, 12.48) | 1.23 (0.23, 6.51) | 0.808 | 5.23 | 80.9 | 0.001> | |
LMWH | 3 | 7537/ 288310 | 1.57 (1.53, 1.62) | 328/ 11900 | 2.41 (2.14, 2.7) | 0.25 (0.01, 6.97) | 0.411 | 185.97 | 98.9 | 0.879 | ||
ACE-I and/or ARB | RAAS-I (ACE-I + ARB) | 7 | 115612/ 172160 | 67.47 (67.24, 67.69) | 9418/ 14442 | 65.58 (64.8, 66.35) | 1.27 (0.3, 5.33) | 0.744 | 6347.10 | 99.9 | 0.619 | |
ACE-I | 5 | 130216/ 164438 | 79.46 (79.26, 79.66) | 4703/ 6414 | 73.68 (72.57, 74.77) | 1.75 (1.22, 2.5) | 0.002 | 17.63 | 77.3 | 0.164 | ||
ARB | 2 | 60/ 941 | 5.6 (4.1, 7.28) | 12/ 107 | 10.93 (5.42, 17.83) | 0.56 (0.28, 1.12) | 0.099 | 0.02 | 0 | 0.001> | ||
ACE-I and/or ARB | 15 | 30688/ 49128 | 62.87 (62.44, 63.3) | 5863/ 12005 | 48.88 (47.98, 49.77) | 1.73 (1.47, 2.05) | 0.001> | 100.62 | 86.1 | 0.007 | ||
Nitrates | 7 | 20513/ 165411 | 12.02 (11.86, 12.18) | 703/ 6658 | 9.45 (8.73, 10.2) | 1.15 (0.6, 2.26) | 0.693 | 76.84 | 92.2 | 0.743 | ||
Variable | Studies (n) | Pooled Prevalence of each Variable in Study Groups | MINOCA Vs Control (OR (95% CI)) | P-value for OR=1 | Cochrane Q | I2 (%) | P-value for Egger Test | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | Â | Â | Â | Sample Size/ Total MINOCA | Pooled Prevalenc in MINOCA | Sample Size/ Total Control | Pooled Prevalenc in Control | Â | Â | Â | Â | Â |
Treatment at Admissiona | Routine Drugs | Statin | 5 | 3111/ 11684 | 25.65 (24.86, 26.45) | 1876/ 8984 | 19.31 (18.48, 20.16) | 3.48 (1.33, 9.1) | 0.011 | 547.13 | 99.3 | 0.275 |
β-blockers | 5 | 3050/ 11684 | 25.95 (25.15, 26.75) | 1772/ 8984 | 18.63 (17.81, 19.46) | 2.34 (1.15, 4.73) | 0.018 | 275.35 | 98.5 | 0.347 | ||
CCB | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | ||
Anti-Platelet | Aspirin | 2 | 1837/ 8964 | 20.49 (19.66, 21.33) | 1270/ 5918 | 21.31 (20.27, 22.36) | 1.07 (0.61, 1.89) | 0.814 | 34.23 | 97.1 | 0.001> | |
Clopidogrel | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | ||
P2Y12-Inhibitor | 1 | 206/ 7266 | 2.84 (2.47, 3.24) | 104/ 4069 | 2.56 (2.09, 3.09) | 1.11 (0.88, 1.41) | 0.382 | NA | NA | NA | ||
Any Anti-Platelet | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | ||
Anti-Coagulant | Warfarin | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
Heparin | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | ||
LMWH | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | ||
Any-Anti-Coagulant | 1 | 375/ 7266 | 5.16 (4.66, 5.69) | 90/ 4069 | 2.21 (1.78, 2.71) | 2.41 (1.91, 3.04) | 0.001> | NA | NA | NA | ||
ACE-I and/or ARB | RAAS-I (ACE-I + ARB) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
ACE-I | 4 | 507/ 2350 | 21.22 (19.57, 22.92) | 234/ 3247 | 5.21 (4.39, 6.09) | 9.22 (1.4, 60.55) | 0.021 | 107.58 | 97.2 | 0.449 | ||
ARB | 1 | 4/ 65 | 6.15 (1.7, 15.01) | 0/ 12 | 0 (0, 26.46) | 1.83 (0.09, 36.17) | 0.692 | NA | NA | NA | ||
ACE-I and/or ARB | 2 | 1314/ 3830 | 33.51 (32.02, 35.01) | 826/ 3556 | 21.97 (20.62, 23.34) | 1.65 (1.41, 1.93) | 0.001> | 1.93 | 48.2 | 0.001> | ||
CombinationTherapy (e.g., Aspirin + Clopidogrel) | 1 | 370/ 2132 | 17.35 (15.77, 19.03) | 151/ 1707 | NA | 2.16 (1.77, 2.65) | 0.001> | NA | NA | NA | ||
Diuretics | 1 | 10/ 97 | 10.31 (5.06, 18.14) | 8/ 98 | 8.16 (3.59, 15.45) | 1.29 (0.49, 3.43) | 0.605 | NA | NA | NA | ||
Insulin | 1 | 1/ 97 | 1.03 (0.03, 5.61) | 2/ 98 | 2.04 (0.25, 7.18) | 0.5 (0.04, 5.61) | 0.574 | NA | NA | NA | ||
Treatment at Dischargea | Routine Drugs | Statin | 10 | 14859/ 24654 | 61.17 (60.56, 61.79) | 7778/ 23747 | 31.95 (31.35, 32.54) | 2.42 (1.43, 4.1) | 0.001 | 1171.03 | 99.2 | 0.678 |
β-blockers | 9 | 10921/ 19093 | 57.95 (57.24, 58.66) | 5247/ 16683 | NA | 2.35 (1.15, 4.79) | 0.019 | 1107.6 | 99.3 | 0.848 | ||
CCB | 2 | 25/ 139 | 17.6 (11.59, 24.5) | 30/ 181 | 12.75 (8.2, 18.09) | 2.19 (0.19, 25.26) | 0.53 | 8.11 | 87.7 | 0.001> | ||
Anti-Platelet | Aspirin | 7 | 8983/ 13182 | 70.8 (70, 71.58) | 3759/ 11744 | NA | 1.85 (0.62, 5.5) | 0.266 | 1262.27 | 99.5 | 0.819 | |
Clopidogrel | 1 | 79/ 171 | 46.2 (38.56, 53.97) | 30/ 180 | 16.67 (11.54, 22.93) | 4.3 (2.62, 7.04) | 0.001> | NA | NA | NA | ||
P2Y12-Inhibitor | 3 | 5032/ 7311 | 69.33 (68.23, 70.41) | 216/ 4319 | 4.15 (3.55, 4.79) | 3.42 (0.16, 71.76) | 0.428 | 47.96 | 95.8 | 0.289 | ||
Any-Anti-Platelet | 1 | 69/ 97 | 71.13 (61.05, 79.89) | 4/ 98 | 4.08 (1.12, 10.12) | 57.91 (19.42, 172.72) | 0.001> | NA | NA | NA | ||
Anti-Coagulant | Anti-Coagulant | 1 | 3.09 (0.64, 8.77) | 3/ 97 | 2.04 (0.25, 7.18) | 2/ 98 | 1.53 (0.25, 9.38) | 0.644 | NA | NA | NA | |
LMWH | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | ||
ACE-I and/or ARB | RAAS-I (ACE-I + ARB) | 1 | 41/ 97 | 61.86 (60.74, 62.97) | 9/ 98 | 9.18 (4.29, 16.72) | 7.24 (3.27, 16.04) | 0.001> | NA | NA | NA | |
ACE-I | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | ||
ARB | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | ||
ACE-I and/or ARB | 4 | 4349/ 9553 | 45.49 (44.49, 46.5) | 3362/ 10559 | 31.65 (30.76, 32.55) | 2.03 (1.36, 3.03) | 0.001 | 40.86 | 92.7 | 0.545 | ||
Nitrates | 2 | 1/ 120 | 0.4 (0, 3.12) | 10/ 282 | 3.44 (1.53, 5.99) | 0.48 (0.07, 3.03) | 0.431 | 0.001> | 0 | 0.001> | ||